Prolonged efavirenz exposure reduces peripheral oxytocin and vasopressin comparable to known drugs of addiction in male Sprague Dawley rats.

Introduction: Several drugs of abuse (DOA) are capable of modulating neurohypophysial hormones, such as oxytocin (OT) and vasopressin (VP), potentially resulting in the development of psychological abnormalities, such as cognitive dysfunction, psychoses, and affective disorders. Efavirenz (EFV), widely used in Africa and globally to treat HIV, induces diverse neuropsychiatric side effects while its abuse has become a global concern. The actions of EFV may involve neurohypophysial system (NS) disruption like that of known DOA. This study investigated whether sub-chronic EFV exposure, at a previously-determined rewarding dose, alters peripheral OT and VP levels versus that of a control, ∆ ⁹ -tetrahydrocannabinol (∆ ⁹ -THC), methamphetamine (MA) and cocaine.
Materials and Methods: To simulate the conditions under which reward-driven behavior had previously been established for EFV, male Sprague Dawley rats ( n  = 16/exposure) received intraperitoneal vehicle (control) or drug administration across an alternating sixteen-day dosing protocol. Control administration (saline/olive oil; 0.2 ml) occurred on odd-numbered and drug administration (EFV: 5 mg/kg, ∆ ⁹ -THC: 0.75 mg/kg, MA: 1 mg/kg, or cocaine: 20 mg/kg) on even-numbered days followed by euthanasia, trunk blood collection and plasma extraction for neuropeptide assay. Effect of drug exposure on peripheral OT and VP levels was assessed versus controls and quantified using specific ELISA kits. Statistical significance was determined by Kruskal-Wallis ANOVA, with p < 0.05. Ethics approval: NWU-00291-17-A5.
Results: Delta-9-THC reduced OT and VP plasma levels ( p  < 0.0001, p  = 0.0141; respectively), cocaine reduced plasma OT ( p  = 0.0023), while MA reduced plasma VP levels ( p  = 0.0001), all versus control. EFV reduced OT and VP plasma levels ( p  < 0.0001; OT and VP) versus control, and similar to ∆ ⁹ -THC.
Conclusion: EFV markedly affects the NS in significantly reducing both plasma OT and VP equivalent to DOA. Importantly, EFV has distinct effects on peripheral OT and VP levels when assessed within the context of drug dependence. The data highlights a possible new mechanism underlying previously documented EFV-induced effects in rats, and whereby EFV may induce neuropsychiatric adverse effects clinically; also providing a deeper understanding of the suggested abuse-potential of EFV.
Competing Interests: The author(s) have no competing interests to declare with regards to the research, manuscript authorship, and/or publication of this article. Excluding income received from the chief employer and financial research support granted to M. Möller from the abovementioned organizations, the author(s) declare that no additional funding or compensation has been received from an individual or corporate entity in addition to there being no personal financial holdings that could be perceived as constituting a personal conflict of interest.
(© 2021 Published by Elsevier Ltd on behalf of International Brain Research Organization.)